Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are administered as first-line therapy for hypercholesterolemia, both as primary and secondary prevention. Besides the lipid-lowering effect, statins have been suggested to inhibit the development of car...
Main Authors: | Yoichi Morofuji, Shinsuke Nakagawa, Kenta Ujifuku, Takashi Fujimoto, Kaishi Otsuka, Masami Niwa, Keisuke Tsutsumi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/2/151 |
Similar Items
-
Cerebrovascular Disease and Statins
by: Luis M. Beltrán Romero, et al.
Published: (2021-12-01) -
Pleiotropic effects of statins
by: Narasaraju Kavalipati, et al.
Published: (2015-01-01) -
Pleiotropic effects of statins: A boulevard to cardioprotection
by: Ankur Rohilla, et al.
Published: (2016-09-01) -
Potential Benefits and Risks Associated with the Use of Statins
by: Nisha Khatiwada, et al.
Published: (2024-02-01) -
Hydrophilic or Lipophilic Statins?
by: Elisenda Climent, et al.
Published: (2021-05-01)